Avid Radiopharmaceuticals
Eric Chellquist is an accomplished professional with extensive experience in quality control and analytical development within the pharmaceutical industry. Currently serving as Senior Quality Control Manager and previously Manager of Analytical Development and Quality Control at Avid Radiopharmaceuticals since 2007, Eric has overseen the release of clinical trial materials and the development of NDA QC test methods for F-18 radioactive tracers. Prior roles include Director of Analytical Services at Genaera Corporation, where Eric managed the manufacture of Squalamine Lactate and developed large-scale crystallization procedures, and QC/Laboratory QA Group Leader at Omnicare Pharmaceutics. Eric holds a Master’s degree in Chemistry from San Francisco State University and a Bachelor’s degree in Chemistry from the University of Massachusetts Amherst.
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.